



Oncoinvent AS
Gullhaugveien 7
N-0484 Oslo, Norway

Tlf: (+47) 22 18 33 05
oncoinvent@oncoinvent.com
Org. nr. 995764458
www.oncoinvent.com

Press Release 02.2019

Oncoinvent signs distribution agreement with radiopharmaceutical wholesaler

Oslo 15. February 2019

Oncoinvent has signed an agreement with the Institute of Energy Technology (IFE) for the distribution of Radspherin (investigational medicinal products) to sites and institutions as part of the company's clinical trial program.

"We are very pleased to have the distribution agreement in place as it is a vital part of our infrastructure going forward. The agreement enables us to provide sites and patients participating in the clinical trial program access to Radspherin in a timely and predictable manner without geographical boundaries." said Jan A. Alfheim, Oncoinvent's CEO.

About Radspherin®

Radspherin® is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. The radium-224 based therapeutic, Radspherin® has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer.



About Oncoinvent

Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to explore and develop multiple technological avenues before selecting a lead product candidate for preclinical testing.

For further information, please contact:

Jan A. Alfheim, Chief Executive Officer

Cell: +47 46 44 00 45

Email: Alfheim@oncoinvent.com

IR enquiries:

Tore Kvam, Chief Financial Officer

Cell: +47 95 93 41 99

Email: kvam@oncoinvent.com